Clinical Trials Logo

Resistant Infection clinical trials

View clinical trials related to Resistant Infection.

Filter by:
  • None
  • Page 1

NCT ID: NCT05482763 Active, not recruiting - Onychomycosis Clinical Trials

Mycosis Culture Collection From Dermatological Isolated

MYCDERM
Start date: July 20, 2022
Phase:
Study type: Observational [Patient Registry]

This pilot, prospective, observational drug study aims to evaluate the efficacy, tolerability and safety of topical and oral antifungals in the treatment of onychomycosis caused by yeasts, dermatophytic moulds and non-dermatophytic moulds as well as correlate the scores in the MALDI-TOF method for the 'identification of genus and species of higher fungi utilizing the comparison between identification in direct optical microscopy, culture examination and optical microscopy and macroscopic and onychoscopic clinical aspects. Furthermore, an optional substudy will evaluate the drug resistance of clinical isolates using molecular or genetic methods.

NCT ID: NCT04636736 Not yet recruiting - HIV Infections Clinical Trials

HIV Drug Resistance Pattern Due to Migration in Poland

Start date: January 1, 2021
Phase:
Study type: Observational

According to the Polish governmental statistics migration of people from Ukraine to Poland is growing and only in year 2020 have come to Poland about a quarter of a million of Ukrainian migrants. As well, more than 40% of those diagnosed with HIV infection in the European Union (EU)/European Economic Area (EEA) in 2018 were also migrants, originating from countries with generalized HIV epidemics, such as Ukraine. Antiretroviral treatment should be started, based, among others, on epidemiological data and evidence of presence of drug resistance mutations in a the population.

NCT ID: NCT03919032 Completed - Cirrhosis Clinical Trials

Bacterial Infections in Patients With Cirrhosis in Argentina: Clinical and Microbiological Characteristics

Start date: October 16, 2018
Phase:
Study type: Observational

In recent years, there has been an increasing prevalence of bacterial infections caused by multiresistant and extremely resistant organisms in patients with cirrhosis. These infections are associated with a worse prognosis, generate difficulties in the management of the patient during hospitalization and increase health costs. The main objective of this project is to estimate the prevalence of infections by multiresistant bacteria in patients with cirrhosis. Additionally, the prevalence of other antibiotic resistance patterns and morbi-mortality in the study population will be evaluated. For these purposes, a multicenter prospective cohort study will be carried out, including patients with cirrhosis who present bacterial infections at the time of admission, or during hospitalization. Performing a study in Argentina on the clinical and microbiological characteristics of bacterial infections in patients with cirrhosis could be very useful to develop new strategies for prevention and treatment of this severe complication.

NCT ID: NCT03837990 Recruiting - Clinical trials for Helicobacter Pylori Infection

One Sequencing Find All for Helicobacter Pylori Infection

Start date: May 1, 2019
Phase:
Study type: Observational

The aim of this study is to Identify antibiotic resistance gene mutations in Helicobacter pylori (HP) and genetic diversity of drug metabolism for antibiotics and proton pump inhibitors (PPIs) in patients with HP infection using next-generation sequencing (NGS). The mutation of host/HP strain will be investigated by single NGS, and the eradication results according to genetic polymorphism of host/HP strain will be analyzed.

NCT ID: NCT03752476 Not yet recruiting - Clinical trials for Antibiotic Resistant Infection

Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria

INOR Blact
Start date: January 1, 2019
Phase:
Study type: Observational

This study evaluates the impact of rank of Beta lactam antibiotics on emergence of mutlidrug resistant bacteria colonization in intensive care It's retrospective case controle study. Cases are colonized patient by multidrug resistant bacteria hospitalized in intensive care during the fist hospitalization in intensive care. Temoin are patients with the same characteristics than case but no colonized by multidrug resistant bacteria.

NCT ID: NCT03655548 Completed - Clinical trials for Urinary Tract Infections

Optimization Management Study of Community Urinary Tract Infections Spectrum

OPTICUR-EBLSE
Start date: October 1, 2016
Phase:
Study type: Observational

Urinary tract infections are the second most common community-acquired infections. Even if extended spectrum β-lactamase-producing Enterobacteriaceae (ESBLE) cause fewer urinary tract infections, their proportion is increasing. New recommendations were published by ANSM in 2015, with specific recommendations for infections due to ESBL-producing Enterobacteriaceae. In this study, we wanted to evaluate the effectiveness of a recall of the 2015 recommendations in the form of a table attached to the ECBU report, associated with hygiene recommendations. Methodology: This prospective, multi-center, non-interventional study was conducted in collaboration with the Labazur laboratory over two 2-month periods, one without modification of the laboratory's practices, the other with the addition of documents on the CBEU report. The primary endpoint was the adequacy of prescriptions to ANSM 2015 recommendations.

NCT ID: NCT03159078 Recruiting - Critical Illness Clinical Trials

Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens

MUSEUM
Start date: May 25, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of polymyxin B as monotherapy versus a combined polymyxin B-carbapenem therapy against multidrug-resistant (MDR) gram negative infections. The investigators intend to evaluate if this synergistic drug regimen correlates with improved outcomes against gram-negative infections in critically ill patients including: better clinical resolution, reduced length of stay at hospital, reduced length of stay at the intensive care unit, and less recurrence of infection.